Status:
TERMINATED
Study With Aminophylline to Attenuate of the Side Effects of Regadenoson
Lead Sponsor:
Rush University Medical Center
Conditions:
Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal ...
Detailed Description
Approximately 250 patients who are referred for a nuclear stress testing of the heart with regadenoson (Lexiscan®) will be recruited to participate in the study. Following regadenoson (administered as...
Eligibility Criteria
Inclusion
- Adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at Rush University Medical Center
Exclusion
- Patient refusal to participate
- Known allergic reaction to aminophylline.
- Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting.
- Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms.
- Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week.
- Pregnant or breast-feeding women.
- Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT01250496
Start Date
November 1 2010
End Date
November 1 2011
Last Update
March 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612